RE:RE:RE:Q3 FINS Review (2 / 5 stars) 1 x revenue for a 57% GM margin, IP/pharma company, you are not assessing an MJ stock though thats the picture you would want to paint. This company is still in early stages and is 25M market cap not a blue chip so your metrics are inconsistent with the size and scope of the Company. Y-Y growth has been massive and they are showing amaizng signals across IP, margins and growth. The fact that you decide to target this company is very intriguing when they actually do solid business and add value.